Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARRIA: Avacopan plus short-term reduced-dose glucocorticoids vs reduced-dose glucocorticoids with rituximab for induction and maintenance in ANCA-associated vasculitis
jRCTs031240416Recruiting
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of avacopan in microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA) and anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) (2 arms), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Primary remission at week 26. Started Mar 2025; status: recruiting.
02
Drugs
avacopan
03
Conditions
microscopic polyangiitis (MPA)granulomatosis with polyangiitis (GPA)anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on jRCTs031240416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240416.